Diamyd Medical AB Cash Flow Statement

Financials in millions SEK. Fiscal year is September - August.

Millions SEK. Fiscal year is Sep - Aug.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May '26 May 31, 2026	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021
Net Income	-287.57	-183.24	-146.57	-120.81	-118.18	-85.88
Depreciation & Amortization	6.94	6.5	10.99	4.87	4.38	0.78
Other Adjustments	81.5	7.93	-1.51	6.42	3.05	0.29
Change in Receivables	5.66	-1.37	1.33	0.07	10.1	-19.57
Changes in Accounts Payable	-7	-4.64	11.72	-1.51	7.43	-5.1
Changes in Accrued Expenses	-	-6.89	8.96	-	-	-
Changes in Other Operating Activities	-	12.02	-14.1	-	-	-
Operating Cash Flow	-190.85	-169.68	-129.18	-110.96	-93.22	-109.47
Capital Expenditures	-3.18	-10.05	-8.03	-11.44	-34.65	-4.23
Purchases of Investments	-99.37	-0.61	-40.35	-0.06	-129.89	-20.48
Proceeds from Sale of Investments	60.2	27.83	20.38	39.91	96.64	157.24
Other Investing Activities	-	-	-	-	-8.82	-
Investing Cash Flow	-42.35	17.17	-27.99	28.4	-76.72	132.53
Long-Term Debt Issued	7.64	14.37	14.81	15.87	-	-
Net Long-Term Debt Issued (Repaid)	7.64	14.37	14.81	15.87	-	-
Issuance of Common Stock	233.25	315.39	135.21	75.27	150	60
Net Common Stock Issued (Repurchased)	233.25	315.39	135.21	75.27	150	60
Other Financing Activities	-17.16	-13.44	-7.73	-4.59	-7.85	-3.28
Financing Cash Flow	223.74	316.32	142.28	86.54	142.16	56.72
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-3.13	0.62	0.12	3.79	8.17	1.22
Net Cash Flow	-9.46	163.81	-14.89	3.98	-27.79	79.79
Free Cash Flow	-194.03	-179.73	-137.21	-122.4	-127.87	-113.69
FCF Margin	-4711.63%	-3583.87%	-3144.04%	-3266.72%	-4946.65%	-25606.50%
Free Cash Flow Per Share	-1.38	-1.60	-1.45	-1.56	-1.67	-1.63
Levered Free Cash Flow	-279.24	-158.47	-127.5	-108.29	-126.36	51.51
Unlevered Free Cash Flow	-290.81	-186.3	-137.02	-128.89	-141.02	-94.42